



Suggested Formula	Haloperidol 5 mg Oral Capsules (Powder Blend, 100 x size #1 Capsules)	FIN	F 008 152
-------------------	---	-----	-----------

SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Haloperidol, USP	0.500	g				
Medisca CapsuBlend®-P	TBD					
Sodium Chloride, USP	As required					

SPECIAL PREPARATORY CONSIDERATIONS

Ingredient-Specific Information

Hygroscopic (protect from moisture whenever possible): CapsuBlend®-P

Light sensitive (protect from light whenever possible): Haloperidol

Suggested Preparatory Guidelines

Non-Sterile Preparation Sterile Preparation

Processing Error / Testing Considerations: To account for processing error considerations during preparation, it is suggested to measure an additional **5 to 9%** of the required quantities of ingredients.

Special Instruction: This formula may contain one or more Active Pharmaceutical Ingredients (APIs) that may be classified as hazardous, please refer & verify the current NIOSH list of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2016. **General Chapter <800> Hazardous Drugs – Handling in Healthcare Settings** was formally published February 1, 2016 in the First Supplement to USP 39-NF 34 and has a delayed **official implementation date of December 31st, 2019**.

This formula must be prepared within the appropriate facilities under adequate environmental conditions, following the necessary guidelines and procedures as stated within *USP 795* and *USP 800*, when handling hazardous drugs. Only trained and qualified personnel must prepare this formula.

All required personal protective equipment (hazardous if applicable), such as but not limited to, lab coat, protective sleeves, gloves both inner and outer if applicable, dedicated shoe covers, hairnet, beard cover, eyewear, appropriate face mask, respirator and face shield, etc., where applicable must be worn at all times.

If applicable, follow all required procedures for hazardous drug handling including but not limited to procurement, transport, storage, preparation, dispensing, administration, clean up (spills) & disposal.

If you are a registered 503B facility, please refer to all relevant guidance documents including but not limited to the Code of Federal Regulations (CFR), Guidance for Industry (GFI) and Compliance Policy Guides (CPGs).

This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.



Suggested Formula	Haloperidol 5 mg Oral Capsules (Powder Blend, 100 x size #1 Capsules)	FIN	F 008 152
-------------------	---	-----	-----------

SUGGESTED PREPARATION (for 100 Size #1 Capsules)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor (*): ____	Processing Error	Qty. to measure
Haloperidol, USP §	0.500	g			
Medisca CapsuBlend®-P	TBD				
Sodium Chloride, USP	As required				

* Takes into account increased batch size conversions and density conversions, if required.

§ Weigh / measure just prior to use.

Preparatory Instruction	
1.	<p><u>Calculate the quantity of CapsuBlend®-P required for 100 x Size #1 Capsules:</u></p> <p>i. Determine the average capsule fill weight by filling and weighing five TARED capsules with the CapsuBlend®-P. Divide the total weight by 5 to obtain <u>average</u> weight. _____ g (A)</p> <p>ii. Quantity of CapsuBlend®-P required per capsule = (A) – 0.005 g* _____ g (B) *quantity of Haloperidol per capsule.</p> <p>iii. Total quantity of CapsuBlend®-P required for the batch = (B) x 100 capsules _____ g (C)</p> <p>iv. Quantity of CapsuBlend®-P to weigh with processing error = (C) x 1.05 ~ 1.09 _____ g (D)</p>
2.	<p><u>Powder preparation:</u></p> <p>A. By geometrical addition, combine and triturate the following ingredients together to form a fine, homogeneous powder blend:</p> <p style="padding-left: 20px;">-Haloperidol -CapsuBlend®-P (D)</p> <p>B. Pass the above powder mixture through a 40 or 50 mesh sieve.</p> <p>C. Mix the sieved powder blend using a manual tumbler mixer to ensure homogeneity.</p>
3.	<p><u>Product transfer (powder-to-capsule filling):</u></p> <p>Fill each of 100 Size #1 capsules with the homogeneous powder blend (Step 2C). Close each capsule tightly.</p> <p>Clean each capsule by placing the capsules in a container filled with Sodium chloride, and then gently rolling the container. Pour the container contents into a 10-mesh sieve, and allow the Sodium chloride to pass through. Finally, roll the capsules on a cloth-covered surface.</p>



Suggested Formula	Haloperidol 5 mg Oral Capsules (Powder Blend, 100 x size #1 Capsules)	FIN	F 008 152
-------------------	---	-----	-----------

4.	<u>Validation technique:</u> The final weight of each capsule (not including capsule shell) should fall between 90 and 110% of the theoretically calculated weight (A), in accordance to USP 795 guidelines.
5.	<u>Product transfer (solid-to-dispensing container filling):</u> Transfer the final product into the specified dispensing container (see “Packaging Requirements”).

SUGGESTED PRESENTATION

Estimated Beyond-Use Date		Packaging Requirements	Tightly closed, light-resistant capsule shells and vials.	
Auxiliary Labels	1	Use as directed. Do not exceed prescribed dose.	6	Protect from light.
	2	Keep out of reach of children.	7	Keep in a dry place.
	3	Keep at room temperature (20°C - 23°C).	8	Consult your health care practitioner if any prescription or over-the-counter medications are currently being used or are prescribed for future use.
	4	Cap tightly after use.	9	May impair mental and/or physical ability. Use care when operating a car or machinery.
	5	Do not take with alcohol, sleep aids, tranquilizers or other CNS depressants.		
Pharmacist Instructions	Add any auxiliary labels specific to the API to the dispensing container as deemed necessary.			
Patient Instructions	Contact your pharmacist in the event of adverse reactions.			

* The BUD is not later than the time remaining until the earliest expiration date of any API or 6 months, whichever is earlier.



Suggested Formula	Haloperidol 5 mg Oral Capsules (Powder Blend, 100 x size #1 Capsules)	FIN	F 008 152
-------------------	---	-----	-----------

REFERENCES

1.	Capsules. In: Allen, LV, Jr. <i>The Art, Science and Technology of Pharmaceutical Compounding</i> . American Pharmaceutical Association; 1998: 91.
2.	Apo-Haloperidol. In: Canadian Pharmacists Association. <i>Compendium of Pharmacists and Specialties, 2007</i> . 179.
3.	Sodium Chloride. In: Rowe RC. <i>Handbook of Pharmaceutical Excipients, 4th Edition</i> . American Pharmaceutical Association; 2003: 556.
4.	Haloperidol. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference, 34th Edition</i> . London, England: The Pharmaceutical Press; 2005: 701.
5.	Haloperidol (Monograph). In: O'Neil MJ. <i>The Merck Index 14th Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2006: Monograph #4598.
6.	Haloperidol. In: Trissel LA. <i>Trissel's Stability of Compounded Formulations, 3rd Edition</i> . American Pharmaceutical Association; 2005: 203.
7.	Haloperidol (Monograph). <i>United States Pharmacopeia XLI / National Formulary 36</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2018: 2019.
8.	Haloperidol Systemic. Thomson Micromedex. <i>USP DI – Drug Information for the Health Care Professional, 26th Edition</i> . Taunton, MA: US Pharmacopeial Convention, Inc; 2006: 1620.
9.	USP <795>. <i>United States Pharmacopeia XLI / National Formulary 36</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2018: 6546.

DISCLAIMER: MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAS PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY, SCHEDULING OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW. MEDISCA NETWORK INC. MAKES NO WARRANTIES WITH RESPECT TO INFRINGEMENT OR NON-INFRINGEMENT BY THE FORMULA OF ANY PATENT OR OTHER INTELLECTUAL PROPERTY OF ANY OTHER PARTY, AND IT IS THE RESPONSIBILITY OF THE PHARMACIST TO INVESTIGATE AND DETERMINE ANY SUCH ISSUE.